Furthermore, ACLY is implicated in the resistance to tamoxifen, palbociclib, and paclitaxel in breast cancer, whereas ACLY inhibition can re-establish sensitivity to these drugs and halts tumor progression (Chen et al., 2020; Ismail et al., 2022; Ismail et al., 2020; Velez et al., 2023). Here, ACLY is linked to breast carcinoma.